Melika Zangeneh Motlagh - Department of oral and maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
Atena Tamimi - Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Reihaneh Golroo - Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Nikoo Hossein-Khannazer - Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pouyan Aminishakib - Department of Pathology, Cancer Institute Hospital, IKHC, Tehran University of Medical Sciences, Tehran, Iran.
Nazanin Mahdavi - Department of oral and maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
Moustapha Hassan - Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
Massoud Vosough - Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden

Oral squamous cell carcinoma (OSCC) represents the most common oral cavity cancer worldwide, being among the ۱۰ most frequent cancers of all types. Only around ۵۰% of patients survive longer than ۵ years in view of currently applied medical procedures of diagnosis and treatment. The delay in diagnosis accounts for the shortening of survival despite advances in treatment protocols. The poor prognosis as well as high occurrence rate exerts a burden on both patients and clinicians. Cancer biomarkers may possibly present cancer profiles of different patients and foreseeing each upcoming therapy response and the subsequent outcomes. Identification of the most fundamental biomarkers in OSCC may lead us to precise detection, which can give rise to earlier diagnosis, more effective treatment options, and more patient oriented prognostic decisions, alleviating the current situation regarding the failure in effectual OSCC management.  In this review, we have outlined the molecular biomarkers for early diagnosis of OSCC and suggested inhibitors through which metastasis and its molecular pathways could potentially be inhibited.  

Oral squamous cell carcinoma, biomarkers, treatment, inhibitors, molecular pathways, targeted therapy